Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Apellis Pharmaceuticals (APLS) EBT (2020 - 2025)

Apellis Pharmaceuticals filings provide 6 years of EBT readings, the most recent being -$58.6 million for Q4 2025.

  • For the quarter ending Q4 2025, EBT fell 142.51% year-over-year to -$58.6 million, compared with a TTM value of $24.1 million through Dec 2025, up 206.21%, and an annual FY2025 reading of $24.1 million, up 206.21% over the prior year.
  • EBT hit -$58.6 million in Q4 2025 for Apellis Pharmaceuticals, down from $216.3 million in the prior quarter.
  • The five-year high for EBT was $283.7 million in Q4 2021, with the low at -$219.2 million in Q2 2021.
  • Median EBT over the past 5 years was -$88.3 million (2022), compared with a mean of -$68.0 million.
  • The largest YoY upside for EBT was 480.48% in 2025 against a maximum downside of 142.51% in 2025.
  • Year by year, EBT stood at $283.7 million in 2021, then crashed by 129.83% to -$84.6 million in 2022, then skyrocketed by 54.33% to -$38.7 million in 2023, then soared by 456.84% to $137.9 million in 2024, then crashed by 142.51% to -$58.6 million in 2025.
  • According to Business Quant data, EBT over the past three periods came in at -$58.6 million, $216.3 million, and -$41.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.